Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. Genzyme has been selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme® and Renagel® are registered trademarks and RenvelaTM is a trademark of Genzyme Corporation. All rights reserved.

This press release contains forward-looking statements including, without limitation, statements about the development of Renvela™ for chronic kidney disease and alternative dosing regimens for the powder formulation of Renvela™. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: additional analysis of the data comparing the powder form of Renvela™ to Renagel®; the results of other studies and whether such results are consistent with this data; the actual efficacy and safety of Renvela™ for chronic kidney disease; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of Renvela™ for chronic kidney disease and the timing of such discussions; the timing and content of submissions to and decisions made by regulatory authorities; the availability and extent of third
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/24/2014)... Mich. , Dec. 24, 2014  Diplomat Pharmacy, ... independent specialty pharmacy, is proud to announce Jennifer ... quality at Diplomat, will take office as the president ... The formal induction ceremony will take place Feb. 28, ... will be held at the Renaissance Center in ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
(Date:12/24/2014)... SAN DIEGO , Dec. 23, 2014 ResMed ... a significant patent infringement action against Chinese medical device manufacturer ... Commission (ITC) ruled today that BMC,s masks listed below infringe ... advertising, or selling these masks in the United ... , iVolve N2 nasal mask , Willow nasal pillows ...
Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Researchers will present,data at the International ... the Posit Science(R) Brain Fitness Program(TM),improves mental ... a condition associated with chemotherapy that results ... by impairing concentration and the,ability to make ...
... Feb. 7 BioNumerik Pharmaceuticals, Inc.,today announced ... global Phase III,clinical trial of BioNumerik,s anticancer ... cancer patients. BioNumerik is,developing Karenitecin (also known ... in the camptothecin class of chemotherapy drugs. ...
Cached Medicine Technology:Neuroscientists Offer Hope for Breast Cancer Patients Suffering From 'Chemobrain' 2BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R) 2BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R) 3
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... 700,000 for each of the 2011 prizes, of which CHF ... CHF 100,000 for their personal use. The prize ... be of considerable significance for medicine. Stefan Jentsch is ... his work on small protein modifiers and their role in ...
... HealthDay Reporter , TUESDAY, Jan. 25 (HealthDay News) ... research finds. Patients with ischemic stroke (involving a blood ... medication and survive if treated at one of these specialty ... published in the Jan. 26 issue of Journal of ...
... Reporter , TUESDAY, Jan. 25 (HealthDay News)-- Prolonged exposure to ... aged 65 and older, a new Danish study finds. ... of road noise, a person,s risk of having a stroke ... that did not translate into a statistically significant risk, but ...
... conducted at Sahlgrenska University Hospital in Gothenburg and at ... of 18 and 65. Half the group was randomly ... half to maintain their usual lifestyle. Both groups ... group increased their physical activity on their own, but ...
... , MONDAY, Jan. 24 (HealthDay News) -- The ... cyclists or pedestrians moving around them isn,t necessarily the result ... a heightened awareness of background movement, a new study from ... person, a part of the brain called the medial temporal ...
... past for children with ACL tears because of the possible damage ... life. With this new technology, surgeons can actually see ... knee, and can safely position the tunnels where they will place ... Medicine Center, and colleagues in the laboratory of Allen R. Tannenbaum, ...
Cached Medicine News:Health News:2011 Louis-Jeantet Prize for Medicine 2Health News:2011 Louis-Jeantet Prize for Medicine 3Health News:2011 Louis-Jeantet Prize for Medicine 4Health News:2011 Louis-Jeantet Prize for Medicine 5Health News:'Stroke Centers' Providing Better Care, Study Finds 2Health News:'Stroke Centers' Providing Better Care, Study Finds 3Health News:Loud Road Noise Linked to Stroke in Older Adults 2Health News:Loud Road Noise Linked to Stroke in Older Adults 3Health News:3-D MRI helps kids with ACL tears -- surgery without harming the growth plate 2
... Indications include painful arthritic deformity of ... the subtalar joint, failed fusion of ... tibial plafond and/or talus where reconstruction ... ankle joint combined with severe arthritic ...
The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
... In 1985, the worlds first ... by Howmedica Osteonics as a means ... wire for trochanteric reattachment procedures. Today, ... papers demonstrating clinical successes, the Dall-Miles™ ...
... The Minimally Invasive Hip Instruments ... THA through a mini-incision using ... set of instruments helps reduce ... invasive THA by optimizing exposure ...
Medicine Products: